Publications (547) María Victoria Mateos Manteca publications

filter_list

2025

  1. Accelerating Myeloma Drug Development: Will Minimal Residual Disease Replace Progression-Free Survival as an Intermediate Surrogate End Point?

    Journal of Clinical Oncology

  2. Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial

    The Lancet Oncology

  3. Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma

    Blood Advances, Vol. 9, Núm. 3, pp. 571-582

  4. Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T-cell redirecting immunotherapy

    American Journal of Hematology, Vol. 100, Núm. 1, pp. 93-102

  5. Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma

    Journal of Clinical Oncology

  6. Correction to: The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development (Blood Cancer Journal, (2025), 15, 1, (15), 10.1038/s41408-025-01212-0)

    Blood Cancer Journal

  7. Daratumumab: a game changer in early myeloma

    Blood

  8. European Myeloma Network Group review and consensus statement on primary plasma cell leukemia

    Annals of Oncology, Vol. 36, Núm. 4, pp. 361-374

  9. Evolution of frontline treatment for multiple myeloma: clinical investigation of quadruplets containing carfilzomib and anti-CD38 monoclonal antibodies

    Annals of Hematology

  10. Health-Related Quality of Life in Patients With Relapsed/Refractory Multiple Myeloma Treated With Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone: An Analysis of Patient-Reported Outcomes From the Phase 3 CANDOR Trial

    Clinical Lymphoma, Myeloma and Leukemia

  11. Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Transplantation Trials

    Clinical Lymphoma, Myeloma and Leukemia

  12. Minimally Invasive Assessment of Peripheral Residual Disease during Maintenance or Observation in Transplant-Eligible Patients with Multiple Myeloma

    Journal of Clinical Oncology, Vol. 43, Núm. 2, pp. 125-132

  13. Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study

    The Lancet Haematology, Vol. 12, Núm. 4, pp. e269-e281

  14. Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma

    New England Journal of Medicine, Vol. 392, Núm. 2, pp. 138-149

  15. The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development

    Blood cancer journal, Vol. 15, Núm. 1, pp. 15